Cognition during active methamphetamine use versus remission

Marilyn Huckans, Stephen Boyd, Grant Moncrief, Nathan Hantke, Bethany Winters, Kate Shirley, Emily Sano, Holly McCready, Laura Dennis, Milky Kohno, William Hoffman, Jennifer M. Loftis

Research output: Contribution to journalArticlepeer-review

4 Scopus citations


Objective: To evaluate whether cognitive performance in adults with active methamphetamine use (MA-ACT) differs from cognitive performance in adults in remission from MA use disorder (MA-REM) and adults without a history of substance use disorder (CTLs). Method: MA-ACT (n = 36), MA-REM (n = 48), and CTLs (n = 62) completed the Neuropsychological Assessment Battery (NAB). Results: The MA-ACT group did not perform significantly worse than CTLs on any NAB Index. The MA-REM group performed significantly (p < 0.050) worse than CTLs on the NAB Memory Index. The MA-ACT group performed significantly better than CTLs and the MA-REM group on the Executive Functions Index. Conclusions: Some cognitive deficits are apparent during remission from MA use, but not during active use; this may result in clinical challenges for adults attempting to maintain recovery and continue with treatment.

Original languageEnglish (US)
Pages (from-to)599-610
Number of pages12
JournalJournal of Clinical and Experimental Neuropsychology
Issue number6
StatePublished - 2021


  • Cognition
  • addiction
  • dependence
  • neuropsychological
  • stimulant
  • substance use disorder

ASJC Scopus subject areas

  • Clinical Psychology
  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Cognition during active methamphetamine use versus remission'. Together they form a unique fingerprint.

Cite this